Internal Medicine, Medical Oncology · Seattle, WA
NPI
1487932398
Since 2011
Specialty
Internal Medicine, Medical Oncology
Code 207RX0202X
Group practices
2
Medicare group memberships
Hospitals
5
Hospital affiliations
1221 Madison St Fl 2
Seattle, WA, 98104
Phone (206) 386-2323
Groups this clinician bills Medicare through
Medicare paid, 2024
$62K
809 services
Medicare patients, 2024
114
Average age 75
Drug cost, 2024
$4.1M
771 prescriptions
Company payments, 2025
$125K
From 17 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Siddhartha H Devarakonda was code 99215 (office e&m - established), 305 times for 67 patients. In total Siddhartha H Devarakonda billed 809 services in 15 codes, and Medicare paid $62K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2023-05-24.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99215 Office E&M - Established | Facility | 305 | 67 | $119.69 | $37K |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Facility | 274 | 70 | $14.31 | $3,922 |
| 99214 Office E&M - Established | Facility | 97 | 47 | $79.61 | $7,722 |
| 99205 Office E&M - New | Facility | 33 | 33 | $158.04 | $5,215 |
| 99232 Hospital E&M - Subsequent | Facility | 28 | 21 | $68.29 | $1,912 |
| 99223 Hospital E&M - Initial | Facility | 23 | 22 | $140.02 | $3,220 |
| 99443 Telephone Services | Facility | 14 | 13 | $84.49 | $1,183 |
By year: 2022 $1.1M for 65,857 services; 2023 $29K for 235 services; 2024 $62K for 809 services.
Lab tests billed to Medicare, 2022
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 36415 Venipuncture Blood Collection | 178 | 46 | $2.96 | $527 |
Medicare prescription drug claims, 2024
In 2024, the drug Siddhartha H Devarakonda prescribed most often to Medicare patients was Tagrisso (Osimertinib Mesylate), with 204 prescriptions and refills. In total Siddhartha H Devarakonda wrote 771 Medicare prescriptions that cost $4.1M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Tagrisso Osimertinib Mesylate | 204 | 204 | 31 | $3.3M |
| Dexamethasone Generic | 57 | 60 | 30 | $615 |
| Prednisone Generic | 46 | 53 | 21 | $164 |
| Eliquis Apixaban | 45 | 60 | 13 | $33K |
| Omeprazole Generic | 29 | 34 | Under 11 | $244 |
| Prochlorperazine Maleate Generic | 28 | 28 | 27 | $353 |
| Alprazolam Generic | 23 | 23 | Under 11 | $50.3 |
| Pantoprazole Sodium Generic | 18 | 22 | Under 11 | $70 |
| Triamcinolone Acetonide Generic | 17 | 18 | Under 11 | $149 |
| Doxycycline Hyclate Generic | 16 | 21 | Under 11 | $557 |
| Ondansetron Odt Ondansetron | 15 | 15 | 12 | $305 |
| Ondansetron Hcl Generic | 14 | 14 | 14 | $85.37 |
| Gilotrif Afatinib Dimaleate | 14 | 14 | Under 11 | $160K |
| Oxycodone Hcl Generic | 13 | 13 | Under 11 | $327 |
| Potassium Chloride Generic | 12 | 20 | Under 11 | $66.77 |
Brand drugs: 308 claims; generic drugs: 463 claims; opioid claims: 32.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Siddhartha H Devarakonda $125K ($125K in general payments such as food, travel and fees) from 17 companies. The largest payer was Janssen Biotech, Inc. with $53K.
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. JNJ | 55 | $53K |
| AstraZeneca Pharmaceuticals LP AZN | 31 | $38K |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 18 | $25K |
| E.R. Squibb & Sons, L.L.C. BMY | 2 | $3,080 |
| Eli Lilly and Company LLY | 2 | $1,663 |
| Catalyst Pharmaceuticals, Inc. CPRX | 3 | $1,480 |
| Amgen Inc. AMGN | 2 | $1,385 |
| Daiichi Sankyo Inc. 4568.T | 7 | $1,187 |
| Acrotech Biopharma Inc. | 1 | $600 |
| Tempus AI, Inc TEM | 2 | $147 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.